AIM ImmunoTech heads into its May 18 earnings date with short interest surging, borrowing costs punishingly high, and a Phase 3 trial announcement doing little to arrest a brutal month-long slide.
Short positioning rebuilt aggressively this week. Short interest as a percentage of the free float jumped 62% over the past seven days to reach 9.1%, nearly doubling from the 5.6% level recorded on April 22. That reversal is striking: SI had been compressing steadily from late March, when it briefly topped 15% of float, before collapsing through early April. The rebound now puts shorts back near meaningful territory, and with days-to-cover at just one day per FINRA's latest fortnightly print, the float remains thin enough to make any positioning shift impactful.
The borrow market tells the most extreme part of the story. Cost to borrow is running at 240% annualised — still enormous by any standard, but it marks a sharp retreat from the 750%-plus levels seen in late March. That earlier spike coincided with peak short interest, and the easing since then reflects both reduced borrow demand as shorts covered and some improvement in share availability. The lending pool is not tight by availability metrics — availability has loosened considerably from the squeeze conditions of six weeks ago — but at 240% CTB, anyone initiating a new short position faces a steep carry cost that limits how long they can hold. The ORTEX short score of 64 is elevated but not at a red-line level, ranking in roughly the 50th percentile of the short-scoring universe.
The Street's view is cautious but not negative, with a single active analyst — Ascendiant Capital — maintaining a Buy on the stock. On April 10, that analyst cut the price target from $22 to $10. That is a material reduction, and the current stock price of $0.52 is deeply below even the revised target. Given the scale of the gap, readers should treat the $10 figure as a directional signal rather than a near-term valuation anchor — it reflects the analyst's view on Ampligen's long-term potential rather than current price dynamics. The bull case centres on Ampligen's oncology pipeline: on April 16, the company announced it has entered Phase 3 trial planning for pancreatic cancer, backed by Orphan Drug status and what the company describes as positive clinical signals. The bear case is straightforward — net losses running at $3.3 million per period, no revenue, and clinical execution risk at every stage.
Insider activity lends modest comfort to holders. The CEO Thomas Equels and Director David Chemerow each purchased shares in early March at prices around $1,000 per share — which, given the current sub-$1 price, almost certainly reflects a pre-reverse-split transaction recorded at pre-split prices. Adjusting for share count, the dollar commitment was $25,000 each, which is small in absolute terms but consistent with a pattern of management buying that stretches back through 2025. Equels has bought at multiple points during the stock's decline, most recently in April 2025. Net insider acquisition over the trailing 90 days stands at approximately $53,000 in value.
The earnings history gives pause. The last print, on March 27, sent the stock down 20% on the day and 15% over the following five sessions. The print before that produced a modest bounce. Going into May 18, the stock has already shed 25% over the past month, closing at $0.52. Peers in the small-cap immunology space have also had a rough week — GNPX fell 15%, ONCY dropped 24%, and ADTX lost 30% — suggesting sector-wide selling pressure rather than company-specific deterioration. What to watch before the May earnings release: whether the Phase 3 announcement translates into any meaningful improvement in borrow costs, and whether short interest continues to rebuild toward the late-March peak.
See the live data behind this article on ORTEX.
Open AIM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
